about
Recent advances in multidisciplinary management of hepatocellular carcinomaHepatitis C in Egypt - past, present, and futureHepatitis C treatment: where are we now?Diagnosis of hepatocellular carcinoma.Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt.Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer stagingEconomic burden of hepatitis C in Egypt: the future impact of highly effective therapies.Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics.Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasionEnhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma.Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting.Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study.The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy.The Diagnostic Impact of C4d, CD68, and NF-κB Expression in the Differentiation Between Recurrent Hepatitis C and Acute Cellular Rejection After Liver Transplantation.Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression.Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum.MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients.Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.The Role of Monocyte/Macrophage and CXCR3 in Differentiation between Recurrent Hepatitis C and Acute Cellular Rejection Postliver Transplantation.Health: redefinedValidation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma
P50
Q26863748-10064745-DFC7-4D3D-85DB-BC41DA8DEE85Q28354329-664D07D8-E671-4902-8AC7-58C0D1914C8CQ30378509-EE9BEC85-4310-453F-A280-DA5A8ACD8FABQ30490554-35C84C5C-7BD6-46F1-B928-715CCC40982DQ35113002-C61AA0B9-EFE7-4A50-934E-D1D1A29A22F3Q35594282-F90CDA3F-18DC-44C4-9432-E3E168949D80Q37279353-B95661AF-E9E7-46AF-83FA-3B9BEAC9B775Q37578500-5553260C-D3E4-46BC-9E21-2AE32F9A1974Q37655092-E44D58FA-2EB7-46CF-92AD-B7BB093E0AF5Q38766496-6C967F71-291D-436B-A1E8-49AFA0322AF2Q38992897-632815AD-E6B7-45DB-AEEE-1289897A4B48Q39452238-801A3E2C-1149-4F1B-916F-DE0C6E931196Q40140466-A829F89F-284A-4E6A-8527-A1AB9C1665EFQ40505587-3EE86985-640A-47CF-99CA-ECDF9990BE16Q46138163-4A59128D-0993-4CFD-82AB-EDAEF9AD8D92Q46617197-081FD831-AC2F-43B4-A69E-547B001CEF8CQ47550714-FD655311-3BB0-4F0C-B910-80519BA4749DQ53141065-6861EBCC-54D0-4F53-ACA1-0145AC02C576Q53700658-176EAABC-7EA5-47C5-A898-AD9EA52A954FQ55023267-FEE400AC-B504-47EA-882A-47D6C954BE15Q91019561-1251FE0D-6355-46A1-9843-E165DA11F870Q91783883-13882CC9-2C05-401B-BD62-F0E3EAA77EA2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Asmaa Ibrahim Gomaa
@ast
Asmaa Ibrahim Gomaa
@en
Asmaa Ibrahim Gomaa
@es
Asmaa Ibrahim Gomaa
@nl
Asmaa Ibrahim Gomaa
@sl
type
label
Asmaa Ibrahim Gomaa
@ast
Asmaa Ibrahim Gomaa
@en
Asmaa Ibrahim Gomaa
@es
Asmaa Ibrahim Gomaa
@nl
Asmaa Ibrahim Gomaa
@sl
prefLabel
Asmaa Ibrahim Gomaa
@ast
Asmaa Ibrahim Gomaa
@en
Asmaa Ibrahim Gomaa
@es
Asmaa Ibrahim Gomaa
@nl
Asmaa Ibrahim Gomaa
@sl
P106
P31
P496
0000-0001-9376-4461